



EVD SURVIVOR PROGRAM IN DRC

F Tshimanga Kazadi, L Fontana, A Legand and A Chaillon

2025-03-06



EVD survivor program

OVERVIEW



- This dataset include **1139 unique individuals**.
- Participants underwent a **mean of 17.94 visits (min=1, max=44)**.
- Participants were followed for a **mean duration of 2.14 years (min=0.03, max=4.52)**.

POPULATION CHARACTERISTICS


Characteristic	N = 1,139
Sex	
Female	627 (55%)
Male	512 (45%)
Age	
29 (1, 81)	
Age group	
≤5 yrs	61 (5.4%)
5-15 yrs	135 (12%)
15-25 yrs	281 (25%)
25-45 yrs	457 (40%)
45-65 yrs	177 (16%)
>65 yrs	24 (2.1%)
occupation	
Agriculteur	315 (30%)
Autre	115 (11%)
Enfant	183 (18%)
Étudiant	45 (4.3%)
Femme au foyer	208 (20%)
Fonctionnaire d'Etat	14 (1.3%)
Minier	18 (1.7%)
Personne d'affaire	44 (4.2%)
Professeur/Universitaire	10 (1.0%)
Professionnel de santé	89 (8.5%)
nombre de visites	1.00 (1.00, 37.00)
nombre de visites psychologiques	1.00 (1.00, 18.00)
n (%); Median (Min, Max)	

Sex and Age distribution

Number of participants over time


Visits

Duration of follow up




COMORBIDITIES AND COMPLICATIONS

COMORBIDITIES



COMPLICATIONS




TECHNICAL NOTE

MISSINGNESS

Percent completeness



APPROACHES FOR MISSINGNESS






Figure 1

- For the downstream analyses, we proposed the **second scenario**.

CLINICAL EVALUATION

TRENDS


labels	6 months	12 months	18 months	24 months	36 months	Average	Improvement
Sensation grattage	6.43	0.00	0.00	0.00	15.18	4.32	-136.08
Murmures vesiculaires	65.62	70.89	63.86	60.71	42.41	60.70	35.37
Troubles sensitifs	100.00	0.00	0.00	0.00	0.00	20.00	100
Troubles equilibre coordination mouvements	100.00	100.00	100.00	100.00	0.00	80.00	100
Troubles sommeil	100.00	100.00	100.00	100.00	100.00	100.00	
Trouble langage	100.00	0.00	0.00	0.00	0.00	20.00	100
Flou visuel	0.00	0.00	0.00	0.00	7.85	1.57	-Inf
Abdomen sensible	0.00	0.00	0.00	0.00	6.81	1.36	-Inf

Clinical evolution of signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.

CLINICAL EVALUATION AT BASELINE

Prevalence


Frequency



Baseline evaluation of signs with a minimum prevalence of 10 cases.


CLINICAL PRESENTATION OVER TIME

CLINICAL PRESENTATION WITHIN THE FIRST 9 MONTHS



Clinical signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.

CLINICAL PRESENTATION WITHIN THE FIRST 3 YEARS



Clinical signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.

PSYCHOLOGICAL EVALUATION


WITHIN THE FIRST 3 MONTHS

Started before EVD

Currently

Since last visit

Worsening since last visit



QUALITY OF LIFE (QALY)


At 6 months

At 12 months

At 24 months

At 36 months

Psychological evaluation at 6 months




DAY BY DAY PREVALENCE TRENDS

Prevalence

Number of individuals


Prevalence of clinical symptoms
(months from ECT exit)



DISEASE BURDEN

DISEASE BURDEN

At 12 months At 24 months At 36 months



THANK YOU

Any questions or suggestions? Contact us: [Anaïs Legand](#) and [Antoine Chaillon](#)